dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
Published 3 years ago • 104 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
2:34
dr. mesa on ruxolitinib in myelofibrosis
-
1:22
jakarta2 update: fedratinib in mf patients previously treated with ruxolitinib
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis
-
1:31
dr. kuykendall on toxicity profiles of ruxolitinib and fedratinib in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
1:40
fedratinib compared to ruxolitinib in the frontline setting for treatment of myelofibrosis
-
1:36
dr. mesa on recent data with momelotinib in mpns